Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, Rossiev V, Dulicek P, Illes A, Pylypenko H, Sivcheva L, Mayer J, Yablokova V, Krejcy K, Grohmann-Izay B, Hasselbalch HC, Kralovics R, Kiladjian JJ; PROUD-PV Study Group.

Lancet Haematol. 2020 Jan 31. pii: S2352-3026(19)30236-4. doi: 10.1016/S2352-3026(19)30236-4. [Epub ahead of print]

PMID:
32014125
2.

Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience.

Onisâi M, Vlădăreanu AM, Nica A, Spînu A, Găman M, Bumbea H, Voican I, Iordan I, Alexandru A, Zdrenghea M, Gheorghita D, Grădinaru S.

Medicina (Kaunas). 2019 Dec 27;56(1). pii: E12. doi: 10.3390/medicina56010012.

3.

LEAM vs. BEAM vs. CLV Conditioning Regimen for Autologous Stem Cell Transplantation in Malignant Lymphomas. Retrospective Comparison of Toxicity and Efficacy on 222 Patients in the First 100 Days After Transplant, On Behalf of the Romanian Society for Bone Marrow Transplantation.

Colita A, Colita A, Bumbea H, Croitoru A, Orban C, Lipan LE, Craciun OG, Soare D, Ghimici C, Manolache R, Gelatu I, Vladareanu AM, Pasca S, Teodorescu P, Dima D, Lupu A, Coriu D, Tomuleasa C, Tanase A.

Front Oncol. 2019 Sep 10;9:892. doi: 10.3389/fonc.2019.00892. eCollection 2019.

4.

Approach to the Adult Acute Lymphoblastic Leukemia Patient.

Sas V, Moisoiu V, Teodorescu P, Tranca S, Pop L, Iluta S, Pasca S, Blag C, Man S, Roman A, Constantinescu C, Rus I, Buse M, Fetica B, Marian M, Selicean C, Berindan-Neagoe I, Petrushev B, Bumbea H, Tanase A, Zdrenghea M, Fuji S, Kitano S, Tomuleasa C; Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation.

J Clin Med. 2019 Aug 6;8(8). pii: E1175. doi: 10.3390/jcm8081175.

5.

Sequential kidney and allogeneic hematopoietic stem cell transplantation.

Tanase AD, Sinescu I, Baston C, Tacu D, Domnisor L, Stefan L, Ranete A, Lipan L, Craciun O, Manea I, Bumbea H, Ciurea SO.

Am J Hematol. 2019 Oct;94(10):E267-E270. doi: 10.1002/ajh.25589. Epub 2019 Aug 13. No abstract available.

PMID:
31342545
6.

Idiopathic thrombocytopenic purpura (ITP) - new era for an old disease.

Onisâi M, Vlădăreanu AM, Spînu A, Găman M, Bumbea H.

Rom J Intern Med. 2019 Dec 1;57(4):273-283. doi: 10.2478/rjim-2019-0014.

PMID:
31199777
7.

Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report.

Cook LB, Fuji S, Hermine O, Bazarbachi A, Ramos JC, Ratner L, Horwitz S, Fields P, Tanase A, Bumbea H, Cwynarski K, Taylor G, Waldmann TA, Bittencourt A, Marcais A, Suarez F, Sibon D, Phillips A, Lunning M, Farid R, Imaizumi Y, Choi I, Ishida T, Ishitsuka K, Fukushima T, Uchimaru K, Takaori-Kondo A, Tokura Y, Utsunomiya A, Matsuoka M, Tsukasaki K, Watanabe T.

J Clin Oncol. 2019 Mar 10;37(8):677-687. doi: 10.1200/JCO.18.00501. Epub 2019 Jan 18.

8.

Nine year follow-up of a rare case of angioedema due to acquired C1-inhibitor deficiency with late onset and good response to attenuated androgen.

Leru PM, Anton VF, Bumbea H.

Allergy Asthma Clin Immunol. 2018 Oct 25;14:69. doi: 10.1186/s13223-018-0274-5. eCollection 2018.

9.

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.

Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators.

Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19.

PMID:
30348538
10.

POEMS syndrome complicated with multiple ischemic vascular events: case report and review of literature.

Găman M, Vlădăreanu AM, Dobrea C, Onisâi M, Marinescu C, Cîşleanu D, Ciufu C, Vasile D, Bumbea H, Voican I.

Onco Targets Ther. 2018 Sep 27;11:6271-6276. doi: 10.2147/OTT.S146221. eCollection 2018.

11.

Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.

Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I.

Crit Rev Clin Lab Sci. 2018 Nov;55(7):501-515. doi: 10.1080/10408363.2018.1499707. Epub 2018 Sep 21. Review.

PMID:
30238808
12.

Laparoscopic splenectomy for hereditary spherocytosis. A case series and review of the literature.

Zaharie F, Muresan MS, Tomuleasa C, Popa G, Blag C, Zaharie R, Zdrehus C, Dragomir M, Bumbea H, Irimie A, Dima D.

Ann Ital Chir. 2018 Jul 11;7. pii: S0003469X18028701. [Epub ahead of print]

PMID:
30221630
13.

Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.

Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.

Crit Rev Clin Lab Sci. 2018 Aug;55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25. Review.

PMID:
29801428
14.

A Challenging Case of Kikuchi-Fujimoto Disease Associated with Systemic Lupus Erythematosus and Review of the Literature.

Găman M, Vlădăreanu AM, Dobrea C, Onisâi M, Marinescu C, Voican I, Vasile D, Bumbea H, Cîşleanu D.

Case Rep Hematol. 2018 Jan 23;2018:1791627. doi: 10.1155/2018/1791627. eCollection 2018.

15.

MECOM, HBS1L-MYB, THRB-RARB, JAK2, and TERT polymorphisms defining the genetic predisposition to myeloproliferative neoplasms: A study on 939 patients.

Trifa AP, Bănescu C, Bojan AS, Voina CM, Popa Ș, Vișan S, Ciubean AD, Tripon F, Dima D, Popov VM, Vesa ȘC, Andreescu M, Török-Vistai T, Mihăilă RG, Berbec N, Macarie I, Coliţă A, Iordache M, Cătană AC, Farcaș MF, Tomuleasa C, Vasile K, Truică C, Todincă A, Pop-Muntean L, Manolache R, Bumbea H, Vlădăreanu AM, Gaman M, Ciufu CM, Popp RA.

Am J Hematol. 2018 Jan;93(1):100-106. doi: 10.1002/ajh.24946. Epub 2017 Nov 10.

16.

Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.

Bagacean C, Tempescul A, Patiu M, Fetica B, Bumbea H, Zdrenghea M.

Onco Targets Ther. 2016 Dec 19;10:31-34. doi: 10.2147/OTT.S115892. eCollection 2017.

17.

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group.

N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.

18.

TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.

Trifa AP, Bănescu C, Tevet M, Bojan A, Dima D, Urian L, Török-Vistai T, Popov VM, Zdrenghea M, Petrov L, Vasilache A, Murat M, Georgescu D, Popescu M, Pătrinoiu O, Balea M, Costache R, Coleș E, Șaguna C, Berbec N, Vlădăreanu AM, Mihăilă RG, Bumbea H, Cucuianu A, Popp RA.

Br J Haematol. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7.

PMID:
27061303
19.

2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and Therapeutic Implications.

Michiels JJ, Tevet M, Trifa A, Niculescu-Mizil E, Lupu A, Vladareanu AM, Bumbea H, Ilea A, Dobrea C, Georgescu D, Patrinoiu O, Popescu M, Murat M, Dragan C, Mihai F, Zurac S, Angelescu S, Iova A, Popa A, Gogulescu R, Popov V.

Maedica (Buchar). 2016 Mar;11(1):5-25.

20.

Early severe preeclampsia with marked platelet dysfunction in association with essential thrombocytemia: case report and discussion.

Onisai M, Voican I, Ciorascu M, Popov V, Bumbea H, Gaman M, Filipescu A, Vladareanu R, Vladareanu AM.

Blood Coagul Fibrinolysis. 2015 Oct;26(7):830-3. doi: 10.1097/MBC.0000000000000352.

PMID:
26196190

Supplemental Content

Loading ...
Support Center